Drug Profile
AV 203
Alternative Names: anti-ErbB3 MAb; AV-203; CAN-017Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator AVEO Pharmaceuticals
- Developer AVEO Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Oesophageal cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Oesophageal-cancer in China (IV)
- 04 Jan 2022 AVEO Oncology regains full worldwide rights to AV 203
- 26 Mar 2021 AV 203 is still in clinical trial for solid tumours in USA in March 2021 (Aveo Oncology pipeline, March 2021)